Vol. 5 No. 9 (2025)
Reimbursement Reviews

Isatuximab (Sarclisa)

Published September 18, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses isatuximab (Sarclisa), 20 mg/mL concentrate for solution for IV infusion.
  • Indication: In combination with bortezomib, lenalidomide, and dexamethasone, for the treatment of patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant.